Skip to Content
MDPIMDPI
Medicines
Submit to Medicines
  • 28 days
    Time to First Decision

Medicines, Volume 12, Issue 2

2025 June - 8 articles

Cover Story: A single-center retrospective trial conducted between 2010 and 2019 copaired aspirin with either prasugrel or ticagrelor in ACS after PCI. The primary composite endpoint of CV death, recurrent ACS, and stroke at one year was reached in 10.3% of the prasugril group and 9.4% of the tecagrilor group (p = 0.303). The rates of major bleeding were similar (3% vs. 2.9%, p = 0.9), respectively. Early treatment discontinuation rates showed a higher percentage in patients taking ticagrelor compared to those on prasugrel (16.7% vs. 9.6%, p = 0.003). Conclusion: both drugs demonstrated no significant difference in efficacy. View this paper
  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (8)

  • Article
  • Open Access
1 Citations
1,750 Views
13 Pages
Download PDF

Dual Antibiotic-Infused Liposomes to Control Methicillin-Resistant Staphylococcus aureus

  • Sourav Chakraborty,
  • Piyush Baindara,
  • Surojit Das,
  • Suresh K. Mondal,
  • Pralay Sharma,
  • Austin Jose T,
  • Kumaravel V,
  • Raja Manoharan and
  • Santi M. Mandal
Medicines2025, 12(2), 14;https://doi.org/10.3390/medicines12020014

22 May 2025

Background: Methicillin-resistant Staphylococcus aureus (MRSA) considered under the category of serious threats by the Centers for Disease Control and Prevention (CDC), urges for new antibiotics or alternate strategies to control MRSA. Methods: Ethos...

Full Article
  • Article
  • Open Access
1 Citations
3,643 Views
14 Pages
Download PDF

Ticagrelor Versus Prasugrel in Acute Coronary Syndrome: Real-World Treatment and Safety

  • Fadel Bahouth,
  • Boris Chutko,
  • Haitham Sholy,
  • Sabreen Hassanain,
  • Gassan Zaid,
  • Evgeny Radzishevsky,
  • Ibrahem Fahmwai,
  • Mahmod Hamoud,
  • Nemer Samnia and
  • Idit Dobrecky-Mery
  • + 1 author
Medicines2025, 12(2), 13;https://doi.org/10.3390/medicines12020013

14 May 2025

Introduction: A direct head-to-head comparison between potent P2Y12 inhibitors: prasugrel versus ticagrelor is still lacking. Purpose: In this single-center study, we sought to address the efficacy and safety of these two third-generation antiplatele...

Full Article
  • Article
  • Open Access
1,860 Views
11 Pages
Download PDF

Assessing the Market Readiness for Medical Cannabis in Greece: A Qualitative Study of Patient Perspectives

  • Christos Ntais and
  • Yioula Melanthiou
Medicines2025, 12(2), 12;https://doi.org/10.3390/medicines12020012

9 May 2025

Background: The introduction of medical cannabis in Greece marks a shift in healthcare policy, yet patient attitudes remain underexplored. Methods: This qualitative study examines the market readiness for medical cannabis through semi-structured inte...

Full Article
  • Article
  • Open Access
1,751 Views
26 Pages
Download PDF

Assessment of Healing Potential of Bombyx mori L. (Silkworm) Derivatives on Second-Degree Burns: Dose-Response and Combination Therapy Analysis

  • Evrydiki Katsikari,
  • Alexandra Kyriaki,
  • Andreas Vitsos,
  • Margarita Vidali,
  • Paschalis Harizanis,
  • Ioannis Sfiniadakis,
  • Maria Kostaki,
  • Dimitra Ieronymaki,
  • Asimina Terezaki and
  • Michail Christou Rallis
  • + 3 authors
Medicines2025, 12(2), 11;https://doi.org/10.3390/medicines12020011

30 April 2025

Background/Objectives: Burn injuries present significant treatment challenges due to the intricate nature of the healing process. Bombyx mori L. (silkworm) derivatives, containing healing-promoting proteins such as sericin and fibroin, as well as the...

Full Article
  • Review
  • Open Access
2 Citations
2,428 Views
11 Pages
Download PDF

Is the Impact of Sodium–Glucose Co-Transporter 2 (SGLT2) Inhibitors on Bone Metabolism and Fracture Incidence a Class or Drug Effect? A Narrative Review

  • George I. Lambrou,
  • Athanasia Samartzi,
  • Eugenia Vlachou and
  • Athanasios N. Tsartsalis
Medicines2025, 12(2), 10;https://doi.org/10.3390/medicines12020010

16 April 2025

Background/Objectives: Type 2 diabetes mellitus (T2DM) has a growing prevalence, even in developed countries. Because of the increase in life expectancy, the number of older people with T2DM is also increasing. The management and handling of these pa...

Full Article
  • Article
  • Open Access
1,080 Views
10 Pages
Download PDF

Retrospective Bayesian Reanalysis of Single Gentamicin Concentrations: A Neonatal Case Series

  • Staci L. Hemmer and
  • Sarah K. Scoular
Medicines2025, 12(2), 9;https://doi.org/10.3390/medicines12020009

10 April 2025

Background/Objectives: Nomograms for adjusting gentamicin therapy in neonates using a single concentration are limited. The Dersch–Mills nomogram is inefficient for short-duration therapies, while the NeoFax nomogram is outdated based on the cu...

Full Article
  • Review
  • Open Access
2,394 Views
14 Pages
Download PDF

Common Bacterial Infections in Persons Who Inject Drugs

  • Michael P. Lorenzo,
  • Kathleen K. Adams and
  • Seth T. Housman
Medicines2025, 12(2), 8;https://doi.org/10.3390/medicines12020008

28 March 2025

Opioid use in the United States has increased dramatically. Bacterial infections are common among persons who inject drugs (PWID), and there is a disparity in the care these individuals receive. As such, outcomes associated with these infections can...

Full Article
  • Case Report
  • Open Access
1,527 Views
9 Pages
Download PDF

Hyponatraemia Induced by Terlipressin in Patients Diagnosed with Decompensated Liver Cirrhosis and Acute Variceal Bleeding

  • Mahmoud Elshehawy,
  • Richel Merin Panicker,
  • Alaa Amr Abdelgawad,
  • Patrick Anthony Ball and
  • Hana Morrissey
Medicines2025, 12(2), 7;https://doi.org/10.3390/medicines12020007

28 March 2025

Background: Hyponatraemia is a rare but potentially life-threatening complication of terlipressin therapy. Case history: In the current case, a 39-year-old female with decompensated liver cirrhosis (Child-Pugh C) and acute variceal bleeding experienc...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Medicines - ISSN 2305-6320
Imprint
Download Flyer